Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | KLF5 | Q13887 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 2/20 | 1.00 |
| ▸ | ATP1B1 | P05026 | 2/20 | 1.00 |
| ▸ | ATP1A3 | P13637 | 2/20 | 1.00 |
| ▸ | ATP1B2 | P14415 | 2/20 | 1.00 |
| ▸ | ATP1A2 | P50993 | 2/20 | 1.00 |
| ▸ | ATP1B3 | P54709 | 2/20 | 1.00 |
| ▸ | FXYD2 | P54710 | 2/20 | 1.00 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ouabain SCHEMBL14633742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL17936503 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL2318232 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL10044992 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24444049 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL18922524 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL24951415 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960066 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL21960068 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 | |
| Ouabain SCHEMBL22824877 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53LMNAHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| EP-4387991-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | Julius-Maximilians-Universität Würzburg (DE) | 2024-06-26 | — | — | EP | claimed |
| WO-2023021113-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2023-02-23 | — | — | WO | claimed |
| CN-109806268-B | Application of ouabain in preparing medicine for treating non-alcoholic fatty liver disease | 南京大学 | 2022-11-29 | — | — | CN | claimed |
| US-20220193053-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | THE JOHNS HOPKINS UNIVERSITY | 2022-06-23 | — | — | US | claimed |
| CN-110960543-A | anti-VEGF-anti-PD 1 combined bispecific antibody for preparing anti-cancer drug | 安徽瀚海博兴生物技术有限公司 | 2020-04-07 | — | — | CN | claimed |
| WO-2010068461-A1 | CO-ADMINISTRATION OF RANOLAZINE AND CARDIAC GLYCOSIDES | GILEAD PALO ALTO, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100130436-A1 | CO-ADMINISTRATION OF RANOLAZINE AND CARDIAC GLYCOSIDES | GILEAD PALO ALTO, INC. (US) | 2010-05-27 | — | — | US | claimed |
| US-7723053-B2 | High-throughput screen for identifying selective persistent sodium channels channel blockers | ALLERGAN, INC. (US) | 2010-05-25 | — | — | US | claimed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | claimed |
| WO-2004072278-A1 | CARDIAC GLYCOSIDE RESISTANT NON-IMMUNOGENIC SELECTION MARKER | AVARIS AB (SE) | 2004-08-26 | — | — | WO | claimed |
| EP-0778768-B1 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | EURO CELTIQUE SA (LU) | 2004-05-26 | — | — | EP | claimed |
| EP-1196177-A2 | USES OF OUABAIN AND OUABAIN-LIKE MOLECULES IN APOPTOSIS RELATED PATHOLOGIES | Corporation du Centre de Recerche du Centre Hospitalier de l'universite de Montreal (CA) | 2002-04-17 | — | — | EP | claimed |
| US-6190921-B1 | Ouabain immunoassay and kit and ouabain labeled with 125I or fluorescent label | LEPPAELUOTO PEKKA JUHANI (FI) | 2001-02-20 | — | — | US | claimed |
| WO-2000074700-A2 | USES OF OUABAIN AND OUABAIN-LIKE MOLECULES IN APOPTOSIS RELATED PATHOLOGIES | CORPORATION DU CENTRE DE RECHERCHE DU CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2000-12-14 | — | — | WO | claimed |
| EP-0988373-A1 | SELECTION MARKER | Karolinska Innovations AB (SE) | 2000-03-29 | — | — | EP | claimed |
| WO-1998055603-A1 | NEW SELECTION MARKER | KAROLINSKA INNOVATIONS AB (SE) | 1998-12-10 | — | — | WO | claimed |
| US-5543157-A | PHARMACEUTICAL INCLUSION COMPOUNDS PROVIDING FAST RELEASE OF DRUG WHEN WETTED WITH WATER, E.G. BODY FLUIDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| EP-0442744-A2 | Treatment of viral disease by glycosides | TSUMURA & CO. (JP) | 1991-08-21 | — | — | EP | claimed |
| US-4434236-A | Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue | E. I. DU PONT DE NEMOURS & CO. (US) | 1984-02-28 | — | — | US | claimed |